Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5095285 | 1.00 | GCGR (0.39) | GCGRKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL4910627 | 0.92 | KDM4E (0.40) | KDM4ESMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL4921299 | 0.92 | KDM4E (0.40) | KDM4ESMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL4918063 | 0.92 | KDM4E (0.40) | KDM4ESMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL4917607 | 0.92 | KDM4E (0.40) | KDM4ESMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL4918451 | 0.92 | KDM4E (0.40) | KDM4ESMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL4913865 | 0.92 | KDM4E (0.40) | KDM4ESMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL4923190 | 0.92 | KDM4E (0.40) | KDM4ESMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL4918926 | 0.92 | KDM4E (0.40) | KDM4ESMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL4892593 | 0.92 | KDM4E (0.42) | KDM4ESMN1; SMN2NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207455-A1 | 5,6-Dialkyl-7-Aminoazolopyrimidines, Their Preparation and Their Use for Controlling Harmful Fungi, and Compositions Comprising These Compounds | BASF AKTINGESELLSCHAFT (DE) | 2008-08-28 | — | — | US | claimed |
| EP-1856118-A1 | 5,6-DIALKYL-7-AMINO-AZOLOPYRIMIDINES, METHODS FOR THE PRODUCTION THEREOF, USE THEREOF FOR CONTROLLING HARMFUL FUNGI, AND SUBSTANCES CONTAINING THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 2007-11-21 | — | — | EP | claimed |
| WO-2006092411-A1 | 5,6-DIALKYL-7-AMINO-AZOLOPYRIMIDINES, METHODS FOR THE PRODUCTION THEREOF, USE THEREOF FOR CONTROLLING HARMFUL FUNGI, AND SUBSTANCES CONTAINING THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 2006-09-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207455-A1 | 5,6-Dialkyl-7-Aminoazolopyrimidines, Their Preparation and Their Use for Controlling Harmful Fungi, and Compositions Comprising These Compounds | CBX7, ERG28, HDHD5 | GCGR 4145/4885KDM4E 560/4885SMN1; SMN2 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.